ALMS
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Alumis reports new Phase 3 data showing rapid and sustained improvements with envudeucitinib in scalp psoriasis, itching, and quality of lifeOct 9, 2026
- Long-term data for envudeucitinib positioned the therapy as a potential new standard for plaque psoriasis, with the highest reported PASI 100 skin clearance among oral therapiesAug 11, 2026
- Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001, a next-generation oral TYK2 inhibitor for systemic lupus erythematosusJul 24, 2025
- Alumis completes enrollment of Phase 3 ONWARD trial of ESK-001, a selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasisMay 29, 2025